Abstract: The insulin-like growth factors (IGFs) are trophic factors whose growth-promoting actions are mediated via the lGF
The insulin-like growth factors (IGF-I and IGF-ll) are polypeptides with both growth-promoting and insulin-like metabolic activities (Krywicki and Yee, 1992) . The mitogenic actions of both IGFs are mediated via the IGF-I receptor, a tyrosine kinase receptor whose activation results in both auto-and intracellular substrate protein phosphorylation (Chou et al., 1987) . The actions of the IGFs are modulated by six structurally related proteins, the IGF binding proteins (IGFBPs) Drop, 1992) . The expression of IGFBPs varies by cell and tissue type Drop, 1992) and is regulated by hormones (Toning et al., 1991; Unterman et al., 1991) and growth factors (Martin and Baxter, 1991; Barreca et al., 1992) , including IGF-I Conover, 1991; Martinet al., 1992) . The IGFBPs transport IGFs to target tissues (Binoux et al., 1991) and alter IOF binding to IUF receptors (McCusker et al., 1991) . Secreted IGFBPs can also bind to extracellular surfaces and target IGFs to mediate growth in specific cell types. For example, in fibroblasts, IGFBP-5 associated with the extracellular matrix (ECM) augments IGF-I action, implying IGFBP-5 increases local access of IGF-I to the IGF-l receptor .
In the CNS, IOF, IGF receptor, and IGFBP expression is high during the fetal period (Beck et al., 1988; Clemmons, 1989; Daughaday and Rotwein, 1989; Sara and Hall, 1990; Liu et al., 1991) , suggesting a role for these factors in normal development. During rat embryogenesis, IGF-I mRNA is detected in regions of active nerve sprouting, spinal ganglia, and facial target regions of the trigeminal nerve (Bondy et al., 1990) . In humans, IGF-I is present in fetal and adult brain and in cerebrospinal fluid (Backstrom et al., 1984; Haselbacher et al., 1985; Han et al., 1988) . In vitro, developing oligodendrocyte progenitor cells require IGF-I to progress to adult, myelin-forming oligodendrocytes (McMorris and Dubois-Dalcq, 1988; Mozell and McMorris, 1988) . IGFs also enhance growth in a variety of neuronal types, including sympathetic and dorsal root ganglia and cloned neuronal cell lines (Martin and Feldman, 1993; Sumantran and Feldman, 1993) .
IGFs and IGFBPs also serve a role in tissue repair and regeneration (Skottner et al., 1990) . IGFs are implicated in accelerated wound healing (Lynch et al., 1989; Steenfos and Jansson, 1992; Sub et al., 1992) and bone remodeling; IGFs modulate osteoblast proliferation and matrix formation (Skottner et al., 1990) . IGFs enhance tissue regeneration, including pancreas , muscle (Jennische and Matejka, 1992) , and kidney (Matejka and Jennische, 1992; Verstrepen et al., 1993) . In the nervous system, IGF infusion enhances motor nerve regeneration (Sjoberg and Kanje, 1989; Near et al., 1992) and, in vitro, stimulates regeneration of adult sensory neurons (Fernyhough et a!., 1993) .
The pattern of IGF expression during nervous system development coupled with its role in repair of nonnervous system tissues lead us to ask whether IGFs and/or IGFBPs could play a facilitory role in nerve regeneration. As an initial Step, we examined IGF-I and IGF-I receptor gene expression after sciatic nerve transection and observed increased transcripts for both factors in lesioned nerves. Schwann cells (SCs) were the main source of IGF-I immunoreactivity until 7 days after nerve transection, when macrophages containing high levels of IGF-I invaded the distal nerve stumps. To address further the role of the IGF axis in SC biology, we determined the in vitro expression pattern of the IGF-I receptor and the IGFBPs. Transfected MT4H I rat SCs expressed the IGF-I receptor and two IGFBPs with molecular mass estimates of 24 and 31 kDa. Addition of IGF-l resulted in SC mitogenesis and enhanced levels of IGFBP-5. We investigated further the mechanism by which IOF-1 regulates IGFBP-5 expression and found that IGF-I protected IGFBP-5 from proteolysis. Collectively, these data support the concept that in response to injury, invading macrophages produce IGF-I and SC express the IGF-I receptor, to facilitate axonal regeneration. This regenerative process may be augmented further by the ability of SC to secrete IGFBPs, which in turn bind SC basement membrane and increase local IGF-I bioavailability. 
MATERIALS AND METHODS

Dulbecco
Sciatic nerve transection
Using aseptic technique, the sciatic nerve of anesthetized (ketamine-rompun, 1 cc/kg) adult Sprague-Dawley male rats (125-150 g; Spartan, Indianapolis, IN, U.S.A.) was exposed at the sciatic notch. After double ligation, the nerve was transected using fine scissors. The nerve stumps were sutured into adjoining muscles. At 3 or 7 days following surgery, the animals were killed by an overdose of ketaminerompun. Both the distal and proximal nerve stumps were removed, stripped of excess connective tissue, and immediately frozen in liquid nitrogen. The contralateral unlesioned sciatic nerve served as the control. Ncrves from 10-12 rats were pooled for each time point. All animal protocols were approved by the institutional animal care and use committee of the University of Michigan.
eDNA probes
A 300-bp rat IGFBP-5 eDNA (Dr. Shunichi Shimasaki, Whittier Institute, La Jolla, CA, U.S.A.), which encodes portions ofthe mature peptide, in pBhuescript SK + plasmid was generated by SacII and HindIII digestion. The IGF-I receptor cDNA was a gift from Dr. Haim Werner (Bethesda, MD, U.S.A.). The eDNA was a 265-bp insert excised from pGEM3 by EcoRl and SmaI digestion. A 1.8-kb PstI-Pstl fragment of a chicken fi-actin was excised from pAct-l (Cleveland et al., 1980) . All eDNA probes were purified using a Magic PCR Prep DNA Purification Kit (Promega, Madison, Wt, U.S.A.).
RNase protection
Riboprobes were prepared from cDNA templates following the manufacturer's protocol (Promega). An exon 3 rat genomic IGF-I fragment was kindly provided by Dr. Peter Rotwein (Washington University, St. Louis, MO, U.S.A.). The rat IGF-I receptor eDNA, inserted in pGEM3, yields a protected band of 265 bp after hybridization (Wemer et al., 1989) . Probes were prepared and RNase protection performed as described previously, using l0-~tgRNA samples (Martinet al., 1991) .
Immunohistochemistry
For immunohistochemical studies, three animals at each time point were examined following seiatic nerve transection. After they were killed, animals were perfused with 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.3). Proximal and distal nerve stumps and the eontralateral control nerves were dissected and postflxed an additional 3 h at 4°C.Portions of sciatic nerves within I cm proximal or distal to the cut site were cryoproteeted with sucrose and embedded in OCT (Miles), frozen above liquid nitrogen, and stored at -80°C. Sections (12 mm) were cut on a cryostat, thaw mounted onto Tespa-coated slides (Pierce Chemicals, Rockford, IL, U.S.A.), and stored at -20°C.
Polyclonal rabbit anti-human IGF-I antibody (UB3-189) was obtained from the NIDDK, National Hormone and Pituitary Program by Drs. Louis P. Underwood and Judson J.
Van Wyk (University of North Carolina, Chapel Hill, NC, U.S.A.) and used at 1:1,000 in phosphate buffer. Rabbit antibodies raised against IGFBP-5 were purchased from Upstate Biotechnology (Lake Placid, NY, U.S.A.), and used at 1:500. Frozen sections were processed for immunostaining employing an immunoperoxidase procedure using the chromogen 3,3 '-diaminobenzidine as described previously (Sullivan and Feldman, 1994) . IGF-I-immunoreactive specificity was tested by use of either preimmune rabbit serum or priniary antibody preabsorbed with excess recombinant lOP-I (I pg/mI; BioSource, Camarillo, CA, U.S.A.).
Anti-IGFBP-5 is a polyclonal antiserum raised against human IGFBP-5 with low cross-reactivity against other IGFBPs. This antiserum can recognize both human and rat IGFBP-5. IGFBP-5 immunoreactivity was blocked by preabsorption of the antiserum with recombinant human IGFBP-5 (1 pg/mI; Austral Biologicals, San Ramon, CA, U.S.A.).
Cell culture
MT4HI rat SCs were maintained in DMEM containing 10% PBS, 100 pMZnSO 4, and 100 pg/mI G418 at 37°Cin a humidified atmosphere with 10% CO2. Upon reaching 80% conflueney, cells were subcultured with trypsin-EDTA into T75 flasks. In some experiments, cells were grown in defined ghial cell medium, designated 03, containing 50 pg/mI transferrin, 10 ng/ml biotin, and 30 nM selenium in DMEM (Bottenstein, 1985) .
Cell proliferation assays
Cells were washed twice and plated with DMEM containing 0.3% PBS at a density of 3 x l0~cells/cm 2 in 96-well plates in increasing concentrations of lOP-I (0.1, 0.3, I, and 3 nM). Cell proliferation was measured at 6, 24, and 48 h after plating with the MTT [3-(4,5-dimethylthiazol-2-yl ) -2,5-diphenyltetrazolium bromide] colorimetric assay (Hansen et a!., 1989) .
methyl-3H] Thymidine ([3H] TdR) incorporation studies
MT4HI cells were plated in 6-well plates (2.5 >< l0c ells/em2) in DMEM with 10% FBS and allowed to grow for 2 days. Medium was removed, and cells were rinsed twice with DMEM and incubated with increasing concentrations of IGF-I (0, 1, and 3 nM) for 24 h at 37°C.After 24 h, [1H]TdR (6 pCi, 6,700 Ci/mol; NEN Du Pont) was added to each well for a 2-h incubation at 37°C, and cells were processed as described previously (Feldman and Randolph, 1991) .
Northern analysis
SCs were plated (3 x l0~cells per T75 flask) in DMEM and 10% PBS. After 2 days, the medium was removed, and cells were rinsed twice in DMEM and placed in G3 media only (03 control) or 03 media containing increasing concentrations (1, 3, and 10 nM) of IGF-I or des( I-3)IGF-I. Des(l-3)IGP-I is an lOP-I analogue with a sixfold higher affinity for the lOP-I receptor but a lower affinity for the IGFBPs compared with ICE-I (Cascieri et al., 1991) . After 24 h, the culture media were collected, RNA was isolated, and northern analysis and densitometry were performed as described previously (Martin and Feldman, 1993) .
Western ligand blotting
Western ligand blots on conditioned media were prepared as described previously (Feldman and Randolph, 1994) . Rinsed membranes were air dried and either placed directly on photostimulable storage phosphorimaging plates and scanned using a phosphorimager (Molecular Dynamics Phosphorlmager, Sunnyvale, CA, U.S.A.) or exposed to XOmat film (Eastman Kodak, Rochester, NY, U.S.A.) at -80°C for I -7 days in the presence of an intensifying screen.
Immunoblotting
Samples of concentrated conditioned media (50 pg of protein) were mixed at a 5:1 ratio with lox sodium dodecyl sulfate-sample buffer [100 mMTris (pH 8), 10mM EDTA, 10% sodium dodecyl sulfate, 100 mM dithiothreitol, 0.1% bromophenol blue, and 20% glycerol], and immunoblots were prepared, incubated for 2 h with IGFBP-5 antiserum (1:1,000), and visualized with enhanced chemiluminescence using the method of Siciliano and colleagues (1992) .
Protease activity experiments
SC conditioned media were collected as described above. Briefly, confluent SC monolayer was washed twice, then incubated in 03 media without growth factors, and collected after a 24-h incubation. The protease activity experiments were performed in cell-free conditions: 100 ng of recombinant human IGFBP-5 was added to 50 p1 of DMEM or conditioned media in the presence or absence of 10 nM JOEl. Samples were incubated at 37°C for 2, 6, or 24 h, then separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. Western immunoblot analysis using IGFBP-5 antiserum was performed as described above.
RESULTS
IGF-I and IGF-I receptor expression following nerve transection
To examine IGF-I and IGF-1 receptor gene expression during wallerian degeneration, we isolated RNA from proximal and distal nerve stumps 3 and 7 days after nerve transection. Nerves from 10-12 animals were pooled for each time point in each experiment, with the uncut contralateral sciatic nerve serving as the control. We detected low levels of lOP-I and IOF-I receptor mRNA in total, uncut sciatic nerves at each time point (Fig. 1A and B) . Following nerve transection, there was an increase in IGF-I gene expression in both the proximal and distal stumps, with maximal IGF-1 expression observed in the distal stump at 7 days ( Fig. IA) . IOF-1 receptor signal also increased in both stumps after nerve transection; however, there was no obvious difference between day 3 and day 7 (Fig. I B) .
To determine which cell type expressed IGF-l in the transected nerve model, we employed immunohistochemistry using anti-IOF-I antiserum. Currently, an antibody to rat IGF-I receptor is not available; therefore, we were unable to perform similar cellular immunolocalization of the receptor. In normal nerves, IOF-I staining was primarily present on SCs, fibroblasts, and capillary endothelial cells. In transverse sections, immunoreactive IGF-I was present in SC cytoplasm, forming a rim around the unstained myelin sheath ( Fig.   2A ). The proximal stumps of both day 3 and day 7 displayed a pattern of IGF-I immunoreactivity similar to intact nerves.
In the distal stumps 3 days after transection, morphological profiles characteristic of nerve injury were observed, including swollen axons and an increased number of endoneurial cells. IOF-I immunoreactivity FIG. 1. IGF-I and CF-I receptor expression following sciatic nerve transection. RNA was isolated from proximal (P) and distal (D) nerve stumps 3 and 7 days after sciatic nerve transection, as described in Materials and Methods. Nerves from 10-12 animals were pooled for each time point in each experiment. A: ICE-I RNase protection assay. An anti-sense RNA probe was transcribed from a 1-kb segment of the IGF-I gene that contained 182 bp of exon-3. Liver RNA protected the appropriate size fragment, whereas RNA from the uncut control nerve (C) produced a barely detectable fragment. Autoradiograph was exposed for 3 days. Data are from one of three representative experiments. B: ICE-I receptor RNase protection. An anti-sense RNA probe was transcribed from a 293-bp ICE-I receptor cDNA. Rat aortic smooth muscle (RASM) RNA protected the expected 265-bp fragment, whereas RNA from the uncut control nerve (C) produced a barely detectable fragment. RNA from nerve proximal (P) and distal (0) to the cut protected the expected 265-bp fragment at 3 and 7 days, with enhanced protection distal to the cut (D) at 7 days. Autoradiograph was exposed for 2 days. Data are from one of two representative experiments.
was detected in SCs, fibroblasts, and capillary endothehal cells (Fig. 2B) . IGF-I immunoreactivity was not observed when the antiserum was preabsorbed with excess recombinant IGF-I, indicating antiserum specificity (data not shown).
Seven days after nerve transection, the pattern of IGF-I immunoreactivity continued. In addition, macrophages, which were strongly IGF-I positive, appeared within the endoneurial space and along the perineurial border, especially in the distal nerve stumps (Fig. 2D) . The IGF-I immunoreactivity within SCs as well as other cellular components remained. In the distal stumps at 7 days, most axons had already degenerated; however, SCs ensheathing axonal debris could still be recognized (Fig. 2C) . The quantity of S-lOO-positive cells rose significantly, indicating SC proliferation. In comparison with the proximal stumps and the control, IGF-I immunoreactivity decreased within the distal stump by day 7. However, more IGF-l-positive macrophages were detected (Fig. 2D) , suggesting macrophages are the primary source of IGF-I at this later time point.
IGF-I promotes SC growth and DNA synthesis
In vitro models provide a valuable means of assessing growth factor action on specific cell types. To understand better the role of the IGF axis in the PNS, we employed cultured MT4HI SCs, a rat cell line in which synthetic promoter elements from the mouse metallothionein-l promoter control the expression of SV4O T antigen. This cell line resembles untransfected secondary SC in both morphology and expression of P() and glial fibrillary acidic protein (Peden et al., 1989; Knight et at., 1993) .
IGF-l is mitogenic in both neuronal and glial cells DiCicco-Bloom and Black, 1988; McMorris and Duhois-Dalcq, 1988; Mozell and McMorris, 1988) . To determine the effects of IOF-I on SC mitogenesis, SCs were grown in DMEM with 0.3% FBS with increasing concentrations of IOF-I for 3 days and cell number was determined by MTT assay (Hansen et al., 1989) . lOP-I at 0.! and 0.3 nM had no effect on growth at 6 and 24 h, but a modest effect was noted at 48 h compared with cells grown in 0.3% FBS alone. However, at I and 3 nM IOF-l, doses known to stimulate glial and neuroblast proliferation (DiCicco-Bloom and Black, 1988; McMorris and Dubois-Dalcq, 1988; Moic!! and McMorris, 1988) , IOF-I increased cell number within 6 h with a subsequent dose-dependent increase at 24 and 48 h (Fig. 3A) . We next examined the effect of IOF-I on [ 3H]thymidine incorporation as a reflection of DNA synthesis. As observed with the MTT assay, IOF-I enhanced [3H]thymidine incorporation threefold after 24 h (Fig. 3B) . These results demonstrate that IOF-I is mitogenic in MT4H I SCs; however, although these data support the concept that IOF-I is mitogenic in primary SCs, they must be interpreted with caution because the current experiments were performed on transfected SCs only.
IGF-I and IGF-I receptor expression in cultured SCs
We speculated that cultured SCs would express lOP-I and IOF-I receptor mRNA similar to the results we observed in the transected sciatic nerve of the rat. To explore this possibility, RNA was isolated from cells grown in serum, defined 03 media, or 03 media with increasing concentrations of lOP-I (Peden et al., 1989 : Knight et a!., 1993 . lOP-I mRNA was not detected with northern analysis or RNase protection (data not shown). As with the transected sciatic nerve preparation, MT4HI SCs expressed mRNA for the lOP-I receptor (Fig. 4) .
Effects of IGF-I on IGFBP gene and protein expression
The IOFBPs play an integral role in the expression and action of the lOPs (Elgin et al., 1987; Clemmons, 1991: Shimasaki and Ling, 1991; Rosenfeld et al., 1993) . Multiple neuronal and glial cell lines, including astrocytes, express one or more IGFBPs at the gene and protein level (McCusker et a!., 1990; Cheung et a!., 1991; . We initially examined IOPBP expression by western ligand blotting in MT4H I SCs grown in defined 03 media for 24 h. When '25l-IOF-ll was used as the ligand, two IGFBPs with molecular mass estimates of 31 and 24 kDa were detected (see Fig. 5A ). In contrast, the 24-kDa IOFBP could not be detected by '251-IGF-l (Fig. SB) . The estimated molecular masses suggested that the 3 l-kDa hand corresponded to IOPBP-5 and the 24-kDa band to IOFBP-4 or IGFBP-6 (Adamo et al., 1992; James ct al., 1993; . lOP-I treatment increased the intensity of the 3l-kDa band in a dose- vealed a 23-kDa band that exhibited a dose-dependent expression in response to LOP-I treatment (Fig. SC) .
IGF-I enhancement of IGFBP-5 expression in SC conditioned media could represent an IOF-I receptormediated event or, alternatively, lOP-I protection of IOPBP-5 from proteolysis (Conover and Kiefer, 1993; . To distinguish between these two possibilities, cells were treated with an LOP-I analogue, des( l-3)IGF-I, that has a sixfold higher affinity for the LOP-I receptor but reduced affinity for IOFBPs (Cascieri et al., 1991) . Des( l-3)IGF-I treatment of SCs decreased the level of measurable IOFBP-5 compared with lOP-I treatment (Fig. SD) . This implies that IGF-L enhances the presence of IGFBP-5 via a receptor-independent mechanism . Finally, equal amounts of protein were e!ectrophoresed for each treatment, making it unlikely that changes in cell number were responsible for the differences observed in the amount of detectable IOFBP-5.
Because lOP-I can alter LGFBP gene expression in multiple cell lines (Krywicki and Yee, 1992), we next examined the effect of IGF-L and LOP analogue treatment on MT4H1 SC IGFBP-5 gene expression. Northern blots were prepared from cells treated for 24 h in 03 media alone or with the addition of 1, 3, or 10 nM lOP-I or des (1-3) lOP-I. Changes were not observed in the 6.0-kb IGPBP-5 transcript with these treatments (Fig. 6 ).
IGFBP-5 proteolysis in SC conditioned media
To demonstrate further that lOP-I enhances the presence of IOPBP-5 via a receptor-independent mechanism, we examined the effect of LOP-I on LGFBP-5 stability in cell-free MT4H1 SC conditioned media. rhIOPBP-5 (100 ng) was incubated in SO ml of either DMEM alone (control) or MT4HI SC-conditioned media in the presence or absence of 10 nM [OF-I (Pig. MT4H1 SC were plated at 4 x iocells/cm2 in DMEM + 10% FBS. After 2 days, the medium was removed and the cells were placed in 03 media ± 1, 3, or 10 nM IGF-l, or des(1-3)IGF-I. After 24 h, the media were collected and western ligand blot analysis was performed as described in Materials and Methods. Data are from one of three representative experiments. A: Western ligand blot analysis after IGF-l treatment. Using 1251-IGF-ll as the ligand, a dose-dependent increase was observed in a 31-kDa form with no change observed in a 24-kDa form under nonreducing condition. Autoradiograph was exposed for 5 days. B: The 31-kDa form was resolved into 29/31-kDa doublet when samples were electrophoresed on 12.5% sodium dodecyl sulfate-polyacrylamide gel. The 24-kDa form IGFBP was not detected when 1251-lt3F-l was the ligand. Autoradiograph was exposed for a week. C: Immunoblot of IGFBP-5. A similar dosedependent pattern was observed on IGFBP-5 immunoblot. IGFBP-5 migrated to 23 kDa under reducing conditions. D: Phosphorimaging analysis of western ligand blots. Western ligand blots were placed directly on a photostimulable storage phosphorimaging plate and scanned using a phosphorimager. The percentage of counts in the total scan was determined from three separate experiments and the results are expressed as a percentage of total counts ± SEM. Autoradiographs from multiple exposures of the experiments shown in A and at least one additional experiment were quantitated using relative optical densities, as described in Materials and Methods. Values are means ±SEM of the ratio of IGFBP-5 mRNA relative optical density to /3-actin relative optical density, expressed as percentage of serum-free untreated control. molecular mass for rhIGFBP-5 under reducing conditions (Fig. 7, lane d) (Kiefer et al., 1992; Conover and Kiefer, 1993) . The same band was also present in the conditioned media after 2 h with or without 10 nM lOP-I treatment with similar densities to the control (Pig. 7, lanes b and c). After 6 h of incubation, the same 34-kDa band was present in the control (Pig. 7, lane h) and in the conditioned media treated with lOP-I (Pig. 7, lane g). In contrast, in untreated conditioned media, a 23-kDa band appeared after 6 h of incubation and coincided with decreased density of the 34-kDa band (Fig. 7, lane f) . These data imply that lOP-I protects IOFBP-5 from proteolysis by an IOPBP-5 protease, in agreement with previous reports (Conover and Keifer, 1993; .
IGFBP expression in transected nerves
To demonstrate that SCs also express IOFBP-5 in vivo, we examined IOPBP-5 immunoreactivity in the transected nerve model. Similar to LOP-I immunostaining, IOPBP-5 immunoreactivity was detected in SCs (Pig. 8A, arrows) as well as axons (Fig. 8A, white arrows) in intact nerves. Reaction product was homogeneously distributed throughout the SC cytoplasm with an intense rim of immunostaining in intact sciatic nerve. Unlike lOP-I, IOPBP-5 immunoreactivity of SCs was not influenced by nerve transection. IOFBP-S immunoreactivity remained localized within SCs in the proximal and distal stumps 3 days after transection (Fig. 8B and C) . The IOFBP-5 antiserum also stained proliferating SCs in the distal stump on day 7 (Pig. 8D). In contrast, the axonal IGFBP-5 immunoreactivity faded after nerve transection (compare Pig. 8A and B).
DISCUSSION
The lOP family of ligands, receptors, and binding proteins is instrumental in normal nervous system development (Daughaday and Rotwein, 1989; Liu et al., 1991) and in the repair of nervous tissues (Sjoberg and Kanje, 1989; Jennische and Matejka, 1992; Near et al., 1992; Fernyhough et al., 1993) . In this study, we examined the pattem of lOP-I and lOP-I receptor gene expression after sciatic nerve transection. In both proximal and distal nerve segments, we observed increased lOP-I and lOP-I receptor transcripts, with a selective enhancement of lOP-I mRNA in the nerve segment distal to the Lesion. Immunohistochemical examination of transected nerves confirmed the presence of lOP-I production by SCs. Our findings parallel those FIG. 7. IGFBP-5 immunoblots revealed IGF-l protection of IGFBP-5 from proteolysis in SC conditioned media (CM). SC conditioned media (50 pI) were incubated with or without 100 ng of rhlt3FBP-5 in the presence or absence of 10 nM OF-I at 37°Cfor 2 or 6 h. The samples were separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions, followed by immunoblotting for IGFBP-5. IGFBP-5 was undetectable in SC conditioned media (a, e). There was no difference between the 34-kDa IGFBP-5 intensities of the conditions with (c) or without (b) IGF-l in SC conditioned media after 2 h of incubation. In contrast, obvious degradation was observed after 6 h of incubation. The intensity of the 34-kDa band without IGF-l (f) decreased significantly in comparison with the conditions plus IGF-l or positive control (g, h) accompanying the appearance of a 23-kDa proteolytic fragment (f). Data are from one of the three experiments with similar results. of Hansson and colleagues who observed patterns of enhanced SC production of lOP-I with peripheral nerve injury (Hansson et al., 1986) .
Similar to our results with LOP-I and lOP-I receptors, SCs, including those that ensheathe motor axons, increase production of nerve growth factor (NOP) and NOF receptors following nerve injury (Taniuchi et a!., 1986 (Taniuchi et a!., , 1988 Heumann et al., 1987) . Transection of selective ventral roots entering the sciatic nerve results in increased NOP receptor expression by SCs associated with degenerating motor neurons, but not intact sensory neurons (Taniuchi et al., 1988) . Like lOP-I and NOP, transforming growth factor-/3 expression increases with nerve transection, particularly in the distal nerve stump (Scherer et al., 1993) . In contrast, the expression of ciliary neurotrophic factor, which is axon dependent, decreases in the distal stumps of transected nerves (Friedman et al., 1992) . We also found that lOP-I promoted in vitro SC growth in a dose-dependent manner. Several polypeptide growth factors are mitogenic to SC in vitro, including transforming growth factor-a, acidic and basic fibroblast growth factors, and platelet-derived growth factor (Eccleston, 1992) . These factors elevate intracellular cyclic AMP which, in the presence of serum, results in SC proliferation (Eccleston, 1992) . Highdose insulin can substitute for serum in the presence of both fibroblast growth factor and platelet-derived growth factor and the cyclic AMP agonist, forskolin (Eccleston, 1992) . Because the mitogenic effects of high-dose insulin are mediated via the lOP-I receptor (Flier et a!., 1986) , the growth-promoting effects of insulin on SC suggest not only the presence of lOP-I receptors on SC but also a physiological role for lOP-I in SC growth.
SC may not be the sole source of polypeptide growth factors in the PNS. Trophic factors may also be produced by different cell types present in transected nerves, including macrophages, endothe!ial cells, and fibroblasts (Blexrud et al., 1990 ). In the current study, we found that macrophages, which infiltrate injured nerves and remove the tissue debris, serve as another source of lOP-I. It is interesting that activated macrophages not only remove tissue debris but also promote SC growth. In vitro, conditioned media of cultured macrophages activated by phagocytosis of myelin debris promote cultured SC growth via mitogenic peptide factors (Baichwal et al., 1988) . Our results suggest one of these mitogenic peptide factors could be LOP-I, which was highly expressed by macrophages in the distal stump 7 days after nerve transection. In contrast to the expression of both LOP-I and the LOP-I receptor by SC in vivo, we did not observe lOP-I gene expression in vitro in MT4H! SC in the current study. These observations imply that (a) the ability of SCs to express lOP-I in vivo is lost in vitro; (b) the observed in vivo expression of lOP-I within SCs of the cut nerve is secondary to other IOF-l-producing cells, including fibroblasts (Clemmons and Van Wyk, 1985) , endothehal cells (Delafontaine and Lou, 1993; Path et al., 1993) , and/or macrophages(Nagaoka, 1990); (c)the LOP-I immunoreactivity in nerve sections is either receptor or binding protein associated; (d) TOP-I immunoreactivity decreases in the distal stumps at 7 days indicate that the ability of SC to express lOP-I is axon dependent. An LOP-I in situ hybridization study of the proximal and distal nerve stumps as well as the neurons of the spinal cord and dorsal root ganglia would be one way to distinguish between these possibilities.
We did observe LOP-I receptor expression in MT4H1 SC. These data parallel our findings on lOP-I receptor expression in proximal and distal transected sciatic nerve segments. Collectively, our results support the concept that one role of growth factor receptors on SC surfaces is to present growth factors to regenerating axons, e.g., lOP-I binding to the lOP-I receptor is one means by which SC could increase the local bioavailability of LOP-I to regenerating axons.
An alternative means of presenting lOP-I to regenerating axons is via the IGPBPs. In the current study, we speculated that SCs secrete TGPBPs which, in turn, bind to SC plasmalemmal matrix and serve as reservoirs for LOP-I. Immunohistochemical studies demonstrated the presence of LOPBPs in the SCs of transected nerves. We then determined whether LOPBPs were produced by MT4H 1 SC. Utilizing western ligand blots, immunoblots, and northern analysis, we report that MT4H I SCs secrete LGFBP-5 and a 24-kDa IOFBP which, according to the molecular mass, could he IOPBP-4 or LOFBP-6 (Kiefer et al., 1992) . The evidence that this 24-kDa IGPBP can be detected only by the ligand 2.SL4OPAI suggests it is IOPBP-6 because IOPBP-6 binds preferentially to lOP-Il and cannot always be detected by ligand blots using '251-IGP-I (Kiefer eta!., 1992) .
Although the precise mechanisms remain unknown, !OPBP-S is associated with cellular growth and differentiation (Mohan et a!., 1989; Andress and Birnbaum, 1992; James et al., 1993; . Tn vitro, IOPBP-S regulates osteoblast proliferation (Mohan et al., 1989; Andress and Birnbaum, 1992) , and expression of IOPBP-5 markedly increases during muscle cell differentiation (James eta!., 1993) . Lt is likely that IOFBP modulation of LOP bioavailabiLity underlies the profound effects IOPBPs have on growth. Recently, Clemmons and colleagues have demonstrated that IOFBP-5 can bind to fibroblast ECM and sequester LOP-I for local fibroblast growth .
The ability of ECM components to dissociate IOPBP-5 from an IGP-I/IGPBP-5 complex further supports the concept that IGPBP-5 targets LOP-I near cell surface lOP-I receptors. Thus, the interactions between SC ECM, IOPBP-S, and LOP-I receptors may regulate local lOP-I bioavailability (Arai et al., 1994) .
In cultured fibroblasts and osteoblasts, IOPBP-S appears to be a stimulatory factor for lOP's mitogenic effects.. Clemmons and colleagues have demonstrated that ECM-associated IOPBP-5 (but not free IGPBP-5 in the media) can potentiate lOP-I's mitogenic effects . Similarly, a truncated 24-kDa IGPBP-S, isolated from osteobLast-conditioned media, can enhance LOP-I-dependent osteobLast proliferation (Andress and Birnbaum, 1992) . The present study reveals the colocalization of TOP-I and IOPBP-5 in a model of nerve transection, implying that IGPBP-5 may play a positive role in modulating TOP-I trophic effects on SC growth, and on axonal regeneration in PNS.
Our experiments also suggest that TOP-I-induced changes in LOPBP-5 are not mediated via the LOP-I receptor. Although LOP-I enhanced the presence of LOPBP-5, des( h-3)IOP-I, an analogue that retains the ability to bind the IGP-I receptor but has a marked decreased affinity for the IOPBPs (Porbes et al., 1988) , did not increase the concentration of IGPBP-5. Thus, an IGP analogue that cannot bind IOPBP-5, but can bind the lOP-I receptor, cannot mimic LOF-T's effects. We also found that lOP-I protected IOPBP-S from proteolysis in a cell-free system. These data imply that the lOP-I-dependent increased concentration of IOPBP-5 is a receptor-independent phenomenon and represents the protection of an extracellular LOF-I/ IOPBP-5 complex from proteolysis by an IOFBP-S protease. In agreement with the current results, Conover and colleagues reported that addition of LOP-I enhanced TOPBP-5 levels in vitro in osteosarcomaconditioned media via a receptor-independent mechanism and that lOP-I protected LOPBP-S from proteolysis Durham et al., 1994) . Similar results were also observed in a fibroblast system by Clemmons and colleagues, and a calcium-dependent serine protease responsible for IOFBP-5 proteolysis has been identified and isolated . Our results suggest the presence of a similar protease that can cleave IOPBP-5 into proteolytic fragments in SC conditioned media.
In summary, although recent work (Eccleston, 1992) , including the current study, emphasizes the importance of neurotrophic factors in nerve growth, the mechanisms underlying successful axonaL regeneration and reformation of axon-SC contacts remain unknown. One theory is that neurotrophins bind to SC surfaces producing a trophic factor-enriched SC plasmalemmal matrix that enhances axonal regrowth (Eccleston, 1992 ). The present study supports this concept; we have shown that, to facilitate regeneration in response to nerve injury, SCs produce LOP-I and IGPreceptor. This regenerative process is augmented further by the ability of SCs to secrete IOFBPs, which, in turn, may bind SC basement membrane and increase local lOP-I bioavailability.
